Found in a strategic location at the Sheraton House, Castle Park only a few minutes walking from the city centre of Cambridge, the new OIA office and lab will be OIA's second location joining our headquarters' office at Davidson House in Reading. OIA Cambridge will have the main purpose to support the haematology and oncology department at Addenbrooke's Hospital, one of the largest and most reputable hospitals and cancer research hubs in the UK and Europe with whom OIA has signed a collaboration and commercial agreement. With this office, OIA will be in a position to launch and extend a premium service covering most of the Golden Triangle.
Oxford Immune Algorithmics is sponsoring the 26th International Workshop on Cellular Automata and Discrete Complex Systems AUTOMATA 2020. The conference aims to:
AUTOMATA 2020 will focus on the theory and applications that many of OIA's own proprietary methods are based upon, in the deep connections of discrete dynamical systems complexity theory and algorithmic information. There will be special sessions and tutorials led by OIA's members on Automata in Machine Learning and on Algorithmic Information Dynamics with a particular interest in aspects of computability in causation, AI and reprogrammability. This shows again OIA's commitment to bridge industry and academia.
We are thrilled to announce that Oxford Immune Algorithmics signed last week a collaboration and commercial agreement with the National Health Service in the UK to serve and continue co-developing Algocyte® in Addenbrooke's Hospital at the Cambridge University Hospitals NHS Foundation Trust, one of the most important hospitals in the UK.
Algocyte® will be deployed at the Department of Paediatric Haematology, Oncology and Palliative Care to help paediatric cancer patients to get supportive monitoring while preventing them to visit the hospital where they are exposed to greater risk of infection due to COVID-19.
We want to thank partners, collaborators and investors that made this possible believing in us and supporting our project to help clinicians and these vulnerable patients.
We are happy to announce that Oxford Immune Algorithmics has been nominated to the OBN awards for the Best Start-up Medtech in the UK. The awards celebrate outstanding achievement throughout the life sciences industry.
OBN is the not-for-profit organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Their 400-plus Member companies are located across the Golden Triangle (Oxford, London and Cambridge) and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland.
The nomination already feels like winning and we are very grateful to OBN for this prestigious nomination.
OIA has become a sponsor and will join CogX 2020 as an exhibitor with a dedicated virtual booth. CogX is the Festival of AI and Emerging Technology and will take place on the 8th-10th June 2020. CogX has gone
Traditionally held in London, CogX 2020 is going Virtual and has become a pop-up 3-day 36 channel online TV network with a Virtual Expo. They expect to beat their audience target and provide even greater connections to everyone involved. I hope you find you at our virtual booth at CogX 2020!
OXFORD IMMUNE ALGORITHMICS IS AWARDED A GRANT TO EXPLORE Applications of automata to areas of causation and machine intelligence
OIA has been awarded a grant by recommendation of the Foundational Questions Institute & Fetzer Franklin Fund, a donor advised fund of the Silicon Valley Community Foundation.
The FQXi catalyses, supports, and disseminates research on questions at the foundations of physics, particularly new frontiers and innovative ideas integral to a deep understanding of reality.
The mission of the Fetzer Franklin Fund is to explore the frontiers of scientific knowledge and to advance breakthroughs towards scientific views of reality that are integrated and relational. the Fetzer Franklin Fund focuses on foundational questions at the frontiers of physics, biology, and consciousness research. The Fund supports work that re-examines the foundations of science, including scientific methodologies for both conventional and frontier research.
The Silicon Valley Community Foundation is the largest regional grant maker in the United States and was conceived to advance innovative philanthropic solutions to challenging problems, engaging donors to make the world a better place for all and
Our CEO, Dr. Hector Zenil, will be delivering the opening Keynote at the Predictive Analytics World summit on May 11, 2020 originally planned to be held in Munich, Germany but now to be held online. He will be talking about Responsible AI in Health Care and Medicine, our research at the forefront of science at OIA and our approach with Algocyte®. Other speakers include Dr. Anna Bauer-Mehren, Head of Data Science at Roche; and Dr. Joran Lookerbol, Director of the Centre for Machine Learning at the Netherlands Institute of Mental Health.
We are sponsors, again, of the Intelligent Health summit where Dr. Kourosh Saeb-Parsy, OIA's Chief Medical Officer, will make a major announcement introducing Project Lancelot, OIA and Algocyte's response to Covid-19 (or its consequences) with our remote health monitoring cutting-edge technology for which OIA was created and we now finds itself in the middle of a pandemic being able to make an important contribution to the challenges posed by the crisis.
Pictures from the previous Intelligent Health summit earlier in 2020 at the ExCel conference centre in London (today, unfortunately, converted into the Nightingale's Hospital because of Covid-19, almost overnight becoming one of the largest hospitals in the world)
We have successfully closed our latest funding round with SFC and KIN Capital leading it, award winning investors, both joining last week our multinational shareholder's board supporting OIA.
This is a major milestone as other startups and companies find it increasingly difficult to find funding in a time of crisis. We are very proud to have SFC and KIN joining OIA's journey and for the trust placed on us by investors of this calibre, it feels very much like validation of what we have been doing in the last 1.5 years developing Algocyte®.
We are thrilled that SFC and KIN have seen value in OIA even (or especially) in times like a pandemic. Their investment will help us respond to the increasing interest we are seeing in our services from the NHS. We will now start our next funding round and it is already looking very promising as we are in advanced talks with some of the largest and greatest VCs in the UK.
According to the organisers, STHLM TECH is the largest startup event in Europe where every geek, hacker, entrepreneur, investor, and designer around Stockholm comes together under one roof.
In this edition, there were 3 special guests announced, including leading investors from Canada and Holland. Omers is behind many of the top startups from Canada including Shopify, and DuckDuckGo. Originally planned to be held at the Hilton Slussen in Stockholm, the event was streamed live from live.sthlmtech.com on Monday 6 April, 2020.
Representing OIA was Dr. Kourosh Saeb-Parsy, our Chief Medical Officer, who gave a great pitch about Algocyte® for which we received useful feedback from investors and organisers who were very optimistic about our approach and business model.
There were around 140 attendants and more than 50 of them voted for the best company pitch:
OIA's Algocyte® pitch won by a large percentage (82%) against two other great startups, and we got very useful feedback from top investors.
Oxford Immune Algorithmics (OIA), like almost every other company and organisation around the world is putting in place contingency plans to downsize operations and send people home to work remotely while trying to be the least disruptive in the development and evolution of our products and goals.
We believe that the current situation is a challenge but also an opportunity. We believe that the current crisis will help humanity better rank priorities, realise that these events can happen and may become the norm if this new family of virus becomes seasonal with different degrees of disruption. We can acknowledge how unprepared was the world to face this challenge and how important would have been to have the means to monitor people's health remotely. Indeed, during a crisis like this one patients are asked to avoid coming to hospitals and surgeries even if they are seriously ill yet unable to get care because of risk of infection. This doesn't have to happen with Algocyte®.
OIA has been working on Algocyte® for almost 2 years and has now a full end-to-end CE Marked (under the CE Medical Device directive) app for remote blood testing and health monitoring that can help with these situations and may even save lives by enabling medical doctors to provide coverage without risk of infection for the health professional or the patient.
We are certain that OIA and Algocyte® will become thus even more relevant because we had our priorities right and we knew this was something the world requires to better handle medical emergencies and, in general, regular patient monitoring.
If our vision resonates with your and you believe that we can make a difference as a health or medical professional to your organisation or practice please contact us at firstname.lastname@example.org
Oxford Immune Algorithmics is chosen as one of the 50 most promising game-changers in the Thames Valley in the UK
Oxford Immune Algorithmics (OIA) has been chosen one of 50 game-changers in the Thames Valley (UK's Silicon Valley) for the creation of Algocyte and our responsible AI approaches awarded by ConnectTVT supported by Deloitte UK, Reading University's Henley Business School, BDB Pitmas and Austin Fraser.
The Thames Valley has the greatest concentration of IT companies in the UK covering the region to the West of London from Swindon to Slough including Oxford and Reading. Other companies with headquarters in Reading and the area include Microsoft, Oracle, Nvidia, DEC, HP, Vodafone, NaturalMotion, Nanopore, among many others.
OIA has been chosen for 'pushing the boundaries with innovation' for its Algocyte platform and solution, the accredited (CE as a medical device), most portable, and sophisticated remote blood testing solution for health monitoring available.
Representing OIA were Kim, Jürgen (CTO and co-founder) and Santiago.
Our Press Release is available here:
With over 1000 attendants at London's largest event venue, the Excel, the sold-out Intelligent Health 2020 event was a success and OIA/Algocyte was one of the featured sponsors where we introduced and promoted our remote blood testing and health monitoring innovative solution.
Attending from OIA were Ago Forcella (COO), Ed Sant'Anna (Chief Strategist), Steeve Tchatchuing and Ines Amri (Business Associates).
OXFORD IMMUNE ALGORITHMICS Partners with the University of Reading to support their local internship scheme
Oxford Immune Algorithmics (OIA) is very proud to have partnered with the University of Reading and welcomes two of their students in Computer Science hired with the partial support of the University of Reading internship scheme and grant. OIA is engaged with the local community and the young people of Reading where OIA's headquarters are located.
We are very excited to share the announcement that we have accomplished a major milestone getting Algocyte® certified under the European Commission medical device directive. Algocyte® is OIA's flagship product, an end-to-end app and solution for remote blood testing and health monitoring based on our proprietary technology (two patents pending no. 1918950.5 and 1918948.9 (UK)).
OIA will be exhibiting at one of the world’s leading summits on AI in medicine, Intelligent Health 2020 on 5 February 2020 at a prime venue, the ExCel, London, U.K. where we will be promoting Algocyte, our flagship product for end-to-end remote blood testing and health monitoring.
Promoted and streamed online worldwide and to the Austin Vita offices in Germany and the U.S., as advertised locally in Reading's giant screen at the train station, six speakers welcomed 80 attendants in an interesting evening to talk about what kind of AI and what type of ethics and responsibilities are there behind AI adoption in healthcare. Instead of only poling more positive pile to AI, the level of discussion in the event was very high and the kind of discussion we would like to see more often.
On the pictures above are our meeting ad on the giant screen followed by Dr. Hector Zenil (CEO of OIA) talk on the challenges and limitations of AI in healthcare and Dr. Kourosh Saeb-Parsy (CMO of OIA) leading the panel discussion on AI in healthcare with panelists Prof. Slawomir Nasuto, and Dr. Weizi Li from the University of Reading, and Geoff Keeling from Ethical Reading and the University of Bristol and the University Cambridge. The event was sponsored by Austin Vita and co-organised by Ethical Reading.
Bringing people interested in closing the gap between academia and industry together, and in cutting-edge science and technology solutions, we at Oxford Immune Algorithmics with Austin Fraser and Austin Vita are organising the AI in Healthcare event.
Our Chief Medical Officer, Dr. Kourosh Saeb-Parsy, video invitation to our event
'AI in Healthcare'
At OIA we believe that automation is not about replacing humans but about scaling intelligence (machine and human) to help healthcare organisations and medical professionals to deal with real human challenges today, such as:
New technologies that harness artificial intelligence (AI) and machine learning (ML) present huge opportunities to transform healthcare, improve the quality of people, and help health professionals.
Followed by an introduction on the ‘limitations, challenges and the future of AI’ by Dr. Hector Zenil (Karolinska Institute, Karolinska Hospital and Oxford Immune Algorithmics), a panel discussion on ‘AI in healthcare’ will be moderated by Dr. Kourosh Saeb-Parsy (Reader of Transplantation at the University of Cambridge, NHS surgeon and Chief Medical Officer of Oxford Immune Algorithmics).
Our panelists are experts in the UK in the areas of healthcare and AI, from government, industry and academia. The discussion will centre around the following questions:
Dr. Kourosh Saeb-Parsy is Chief Medical Officer at Oxford Immune Algorithmics Ltd. MD & PhD in Neurosciences (Cambridge), NHS Transplant Surgeon, a University Reader & Leader of his own lab at the University of Cambridge (specialised in immunogenicity of regenerative cellular therapies) has over 15 years experience in biotech companies, director of the Cambridge In Vivo Assessment Platform & the Cambridge Biorepository for Translational Medicine.
Prof. Slawomir Nasuto is a Deputy Research Lead of the Biomedical Sciences and Biomedical Engineering Research Division within the School of Biological Sciences at the University of Reading. Prof Nasuto heads the Brain Embodiment Laboratory, an interdisciplinary facility within the School of Biological Sciences comprising two experimental laboratories performing research in Brain Computer Interfaces and cell cultures, and using complex systems science approaches to characterise the resulting data. His research on phase synchronisation, functional connectivity and complex evolving networks informs, and in turn benefits from, interrogating cognitive processes and more directly nervous system. He is interested in the use of BCI and neurofeedback for therapeutic applications and to affect human behaviour, as well as wider applications of complex systems science, swarm intelligence and machine learning to uncover complex relationships hidden within data. He published over 180 research articles in books, journals and international peer-reviewed conferences in the related areas.
Geoff Keeling is a Research Assistant at the Leverhulme Centre for the Future of Intelligence at the University of Cambridge. He is also a PhD candidate in the Philosophy Department at the University of Bristol. Geoff is interested in the ethics of artificial intelligence, and how we can make ethical decisions when we are uncertain about the consequences of our actions.
His talk examines what informed consent might look like in a future containing artificial doctors, and considers the implications for algorithmic decision-making in other areas such as finance and advertising.
Dr. Weizi (Vicky) Li, is Associate Professor of Informatics and Digital Health, Deputy Director in Informatics Research Centre, Henley Business School, University of Reading. Her research focuses on digital health, integrated system, artificial intelligence and machine learning applications in healthcare. She is a Fellow of the Chartered Institute of IT (FBCS). Her research of integrated clinical pathway system has been successfully commercialised and she has been scientific advisor of the company who provide mobile healthcare and data platform for 3000 hospitals in China. Her research impact of improving healthcare quality and efficiency using data platform and AI is recognised as one of winners of O2RB Excellence in Impact Awards in 2018, supported by University of Oxford Economic Social Research Council Impact Acceleration Account. Her research with NHS on “Applications and Implications of Machine Learning: Understanding and Predicting Healthcare Resource Usage and Patient Risk for Improved Population Engagement” has been awarded Economic Social Research Council grant in 2018. Her other research projects in healthcare are funded by private companies, NHS and Innovate UK.
Dr. Hector Zenil is a mathematician and holds degrees in Logic (MPhil, Paris), Computer Science (PhD, Lille), & Logic & Epistemology (PhD, Paris). He has over 20 years experience in academia & industry. An authority in complexity & causality with over 100 papers published as a Senior researcher & faculty member of the University of Oxford, & as lab leader at the Karolinska Institute (awarding institution of the Nobel Prize in Medicine). He has over 100 paper in the top journals of DNA research, machine intelligence, bioinformatics, physics and complexity.
Dr Jurgen Riedel is a physicist (PhD, Germany) with interests in and contributions to classical field theory, quantum gravity, & cellular automata. Member of the board of directors of the scientific Paris-based lab LABORES & its Algorithmic Nature Group. He has over 20 years experience in Business Intelligence, data visualisation & data science working for large companies such as UBS, Citibank, Volkswagen, & Eon.
In a prime location next to Reading’s rail station at the Thames Tower (floor 12), Reading RG1 1LX (30 min from Oxford and 25 min from London's Paddington by train)
By train, the venue is literally 1 min away from Reading’s rail station. By car, you can park at the NCP rail station parking place and other parking facilities around in the city centre at a discounted (and very cheap) price after 6 PM (behind the Thames Tower building).
Please sign up for free at:
(limited to only 150 people)
The event will be streamed to the U.S. and Germany. Our CTO, Dr. Jürgen Riedel, invites the German crowd
Follow us by subscribing to our AI in healthcare newsletter at:
Organised in partnership with the NHSx, Intelligent Health UK is the World’s Leading AI in Medicine Summit, 5 February 2020 | London | UK
OXFORD UNIVERSITY INNOVATION SPONSORS THE PLANTING OF A TREE IN Wytham Woods IN HONOUR OF OIA'S LAUNCH
OIA's first anniversary was this past September 25th and the University of Oxford planted a 4-year old beech tree in honour of Oxford Immune Algorithmics (OIA) at the Oxford University premises in Wytham Woods in Oxford where a plaque dedicated to OIA was unveiled. The tree will be taken care of for 15 years after which the plaque will be placed on the base of the tree for the hundreds of years that the tree will hopefully live and for next generations to take care. This is an initiative to create awareness and help replant an area of the woods.
Young trees like these ones can absorb CO2 much faster than larger trees as their metabolism is faster between 4 and 15 years old. Our ambitious goal at OIA for the next 15 years is to become the leaders in healthcare technology and offer an affordable scalable solution to help cure all curable human diseases. Helping plant the tree were personnel from Oxford University Innovation and OIA, including OIA's CEO Dr. Hector Zenil. OIA is honoured to have received this distinction from the 8 startups and spinouts from Oxford University that launch in average every year.
OIA will be at the the early stage life sciences investment event to be held at Level39 in Canary Wharf, London, January 20, 2020.
On the 15-16 October 2019, OIA is attending The Global Innovation and New Technology Health Event at the Chelsea Football Club Stadium in London where it is showcased the leading health tech startups from around the world.
An application of our research in causal models in molecular biology has been published today in one of the finest journals in molecular biology, Nucleic Acids Research (Oxford). This is the first meaningful application of algorithmic complexity to experimental cell biology beyond previous methods based on statistical approaches. It strengthens our position as pioneers in the area of causal knowledge discovery and it propels us forward as a validation of our work and technology.
Our paper shows how our methods identify DNA sequences holding key information about genetic regulation.